RSLS Valuation

ReShape Lifesciences Inc

Add to Watchlist

Advanced Chart

3.350

+0.33(10.927%)1D

Overview
Forecast
Valuation
Earnings

RSLS Relative Valuation

RSLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RSLS is overvalued; if below, it's undervalued.

Historical Valuation

ReShape Lifesciences Inc (RSLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.63 is considered Undervalued compared with the five-year average of -198.58. The fair price of ReShape Lifesciences Inc (RSLS) is between 629.60 to 637.02 according to relative valuation methord. Compared to the current price of 3.32 USD , ReShape Lifesciences Inc is Undervalued By 99.47%.

Relative Value

Fair Zone

629.60-637.02

Current Price：3.32

99.47%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.33

P/B

Median3y

0.67

Median5y

0.43

-64.44

FCF Yield

Median3y

-334.07

Median5y

-235.41

Competitors Valuation Multiple

The average P/S ratio for RSLS's competitors is 515.73, providing a benchmark for relative valuation. ReShape Lifesciences Inc Corp (RSLS) exhibits a P/S ratio of 0.58, which is -99.89% above the industry average. Given its robust revenue growth of -42.75%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RSLS.O

ReShape Lifesciences Inc

0.58

Average P/S: 515.73

-42.75%